Key Takeaways
- Citi has cut Moderna’s rating to Sell from Hold while lifting its price target from $60 to $80.
- In Wednesday’s premarket session, Moderna stock declined 5.7% to $191.96.
- The biotech’s shares have surged approximately 222% from their mid-August lows following promising cancer vaccine trial results.
- According to Citi, justifying a $200 share price would demand roughly $13 billion in yearly oncology salesānearly seven times the firm’s current projections.
- The broader analyst community maintains a Hold consensus rating, with a mean price target of $110.44 that suggests potential downside of approximately 45%.
Investment bank Citi has adopted a pessimistic stance on Moderna. Research analyst Geoff Meacham downgraded the biotech company to Sell from Hold in a Wednesday research note.
The rating change arrives on the heels of an extraordinary rally in Moderna’s stock price. Shares have soared approximately 222% since reaching their August lows.
This remarkable advance was triggered by encouraging clinical results for intismeran autogene, Moderna’s experimental cancer therapy being co-developed with pharmaceutical giant Merck. The treatment successfully achieved its primary endpoints in a Phase 3 melanoma trial.
Market participants responded enthusiastically to the announcement. However, Citi believes investor optimism has far exceeded reasonable expectations.
While Meacham elevated his price objective to $80 from $60, this new target still represents approximately 61% potential decline from Moderna’s most recent closing price of $203.46.
Following the downgrade announcement, Moderna shares fell 5.7% to $191.96 during Wednesday’s premarket trading session.
The Case for Downgrading
Citi’s primary concern centers on valuation metrics. Moderna’s market capitalization has expanded to approximately $80 billion, placing it in the same range as Regeneron Pharmaceuticals.
Yet the underlying financial projections don’t support such a comparison. Wall Street consensus forecasts project Moderna will achieve around $5.8 billion in revenue alongside $1.1 billion in net income by 2030.
Meanwhile, Regeneron is anticipated to deliver $22.7 billion in revenue and $8 billion in net income during that same timeframe. According to Citi, this substantial disparity indicates the market is already pricing in significant pipeline achievements that remain highly uncertain.
Even under an optimistic scenario where Citi assigned intismeran a 100% probability of success throughout its major oncology programs, the investment bank calculates this would only justify approximately $100 per share. Reaching $200 would necessitate about $13 billion in annual cancer treatment revenueānearly seven times Citi’s existing forecasts.
Meacham characterized such revenue expectations as highly improbable.
Awaiting Critical Data Points
Citi acknowledges the encouraging top-line outcomes from the INTerpath-001 clinical trial. The study successfully achieved both its recurrence-free survival and distant metastasis-free survival primary endpoints.
However, detailed numerical data has yet to be disclosed. Critical information including hazard ratios, comprehensive safety profiles, and manufacturing scalability considerations remain undisclosed.
According to Meacham, a hazard ratio in the vicinity of 0.72 would represent a clinically meaningful result. A figure of 0.65 or below would constitute an unambiguous success.
As a reference point, an earlier Phase 2 trial demonstrated a five-year hazard ratio of 0.51. This establishes elevated expectations for the forthcoming Phase 3 data release.
Additionally, melanoma demonstrates particularly strong responses to immunotherapy relative to other cancer types. Meacham emphasized that positive results in melanoma don’t necessarily translate to efficacy in kidney cancer, lung cancer, or bladder cancer, each presenting distinct biological characteristics and competitive treatment landscapes.
The next significant data presentation is scheduled for the European Society for Medical Oncology conference in late October.
Analyst sentiment on Moderna remains divided across Wall Street. Among the 20 analysts tracking the stock, six maintain Buy ratings, the majority assign Hold ratings, and just a handful recommend selling.
The consensus price target among Street analysts stands at $110.44. This level implies potential downside of roughly 45% from present trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
